PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31473909-8	2019	The larval survival rate under fluconazole (up to 80 mug mL-1) and nystatin (up to 20 mug mL-1) was > 90% and for CAgNC it was 40% at 36 h post-exposure (hpe).	Nystatin	67-75	2'-5' oligoadenylate synthetase 1B	Mus musculus	90-94
31091145-7	2019	Nystatin-mediated reduction of intracellular K+ with corresponding increase in intracellular Na+ in wild-type cells to mimic conditions of HX greatly suppressed vanadate-stimulated and A23187-stimulated KCNN4 activity in those wild-type cells.	Nystatin	0-8	potassium calcium-activated channel subfamily N member 4	Homo sapiens	203-208
30015970-7	2018	Nystatin, a lipid raft inhibitor, inhibited the activation of Cav-1 and markedly reversed RANKL-induced gastric cancer cell migration.	Nystatin	0-8	caveolin 1	Homo sapiens	62-67
29846682-10	2019	The MIC90 of amphotericin B and nystatins were 2 and 4 mug/ml, respectively, against either C. albicans or non-albicans Candida spp.	Nystatin	32-41	histocompatibility minor 13	Homo sapiens	128-131
30045641-10	2018	CONCLUSIONS: The antifungal therapies could be more effective if it consider, qualitative salivary characteristics as pH, that could determine the susceptibility of species of Candida to at least to nystatin, which is the most used antifungal for treatment to oral candidiasis in patients with DM2.	Nystatin	199-207	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	294-297
29957841-7	2018	The cholesterol-sequestering agent nystatin partially reversed DR5 clustering and DISC formation, preventing apoptosis triggered by the combination of beta-elemene and TRAIL.	Nystatin	35-43	TNF receptor superfamily member 10b	Homo sapiens	63-66
29957841-7	2018	The cholesterol-sequestering agent nystatin partially reversed DR5 clustering and DISC formation, preventing apoptosis triggered by the combination of beta-elemene and TRAIL.	Nystatin	35-43	TNF superfamily member 10	Homo sapiens	168-173
30015970-7	2018	Nystatin, a lipid raft inhibitor, inhibited the activation of Cav-1 and markedly reversed RANKL-induced gastric cancer cell migration.	Nystatin	0-8	TNF superfamily member 11	Homo sapiens	90-95
25996834-6	2016	Ex-vivo apparent permeability of the freeze-dried SLN across everted rat intestine was 24 x 10-6 at 37  C and 5.6 x 10-6 at 4  C. The presence of endocytic process inhibitors like chlorpromazine and nystatin reduced it to 18.8 x 10-6 and 20.2 x 10-6, respectively, which established involvement of endocytic mechanism in the uptake of SLN.	Nystatin	199-207	sarcolipin	Rattus norvegicus	50-53
29720121-13	2018	Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance.	Nystatin	0-8	estrogen receptor 1	Homo sapiens	42-44
29720121-13	2018	Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance.	Nystatin	0-8	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	45-50
29720121-13	2018	Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance.	Nystatin	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
29183998-8	2018	An inhibitor of that process, nystatin, blocked both the endocytosis and proteolytic cleavage of N-cadherin induced by CS and also suppressed BT-549 cell invasion.	Nystatin	30-38	cadherin 2	Homo sapiens	97-107
29058908-5	2017	The PDNPs were discovered to be internalized through three specific pathways, that is, Caveolae-, Arf6-dependent endocytosis, and Rab34-mediated macropinocytosis (55%, 20% and 37% of uptake inhibition by nystatin, Arf6 knockdown, and rottlerin, respectively).	Nystatin	204-212	RAB34, member RAS oncogene family	Homo sapiens	130-135
27451953-9	2017	Antifungal susceptibility results revealed that F. oxysporum is resistant to copper sulphate (up to 200 mug mL-1 ) and sensitive to nystatin (up to 40 mug mL-1 ).	Nystatin	132-140	L1 cell adhesion molecule	Mus musculus	155-159
28272479-5	2017	By contrast, Far1 is stabilized by sequestering cholesterol with nystatin.	Nystatin	65-73	fatty acyl-CoA reductase 1	Homo sapiens	13-17
26915736-6	2016	Results showed that disturbing lipid rafts with nystatin could inhibit MF-induced EGFR clustering, indicating that it was dependent on intact lipid raft.	Nystatin	48-56	epidermal growth factor receptor	Homo sapiens	82-86
27464757-1	2016	This study was designed to assess the antifungal/anti-biofilm and hemolytic properties of two polyene antibiotics, amphotericin B (AMF) and nystatin (NYS), attached to the surface of magnetic nanoparticles (MNP) against clinical isolates of Candida species and human red blood cells, respectively.	Nystatin	140-148	FERM domain containing 7	Homo sapiens	150-153
29713320-15	2018	Structurally altered CRP induces leukocyte-endothelial interaction and induces ROS formation in leukocytes, the latter can be abrogated by blocking lipid raft-dependent signaling pathways with Nystatin.	Nystatin	193-201	C-reactive protein	Homo sapiens	21-24
29145158-6	2018	rOmpU-induced IL-8 expression was inhibited by interference of lipid raft formation with nystatin, but not by blocking the formation of clathrin-coated pits with chlorpromazine.	Nystatin	89-97	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
29123224-1	2017	A novel red-emitting phosphor NaY9(SiO4)6O2:Sm3+ (NYS:Sm3+) was synthesized and the X-ray diffraction and high-resolution TEM testified that the NYS compound belongs to the apatite structure which crystallized in a hexagonal unit cell with space group P63/m.	Nystatin	145-148	tumor protein p63	Homo sapiens	252-255
28041915-4	2017	Molecular docking, performed on the obtained hit compounds from virtual screening, indicated nystatin to be the only active lead against the receptors iGluR5 kainate receptor (1VSO), CGRP (3N7R), beta2 adrenoceptor (3NYA) and Dopamine D3 (3PBL) with a high binding energy of -11.1, -10.9, -10.2 and -12kcal/mole respectively.	Nystatin	93-101	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	183-187
28041915-4	2017	Molecular docking, performed on the obtained hit compounds from virtual screening, indicated nystatin to be the only active lead against the receptors iGluR5 kainate receptor (1VSO), CGRP (3N7R), beta2 adrenoceptor (3NYA) and Dopamine D3 (3PBL) with a high binding energy of -11.1, -10.9, -10.2 and -12kcal/mole respectively.	Nystatin	93-101	adrenergic receptor, beta 2	Mus musculus	196-214
27200276-1	2016	OBJECTIVES: The purpose of this ex vivo study was to compare the antifungal activity of a synthetic peptide consisting of 15 amino acids at the C-terminus of human beta-defensin 3 (HBD3-C15) with calcium hydroxide (CH) and Nystatin (Nys) against Candida albicans (C. albicans) biofilm.	Nystatin	223-231	defensin beta 103B	Homo sapiens	164-179
27200276-1	2016	OBJECTIVES: The purpose of this ex vivo study was to compare the antifungal activity of a synthetic peptide consisting of 15 amino acids at the C-terminus of human beta-defensin 3 (HBD3-C15) with calcium hydroxide (CH) and Nystatin (Nys) against Candida albicans (C. albicans) biofilm.	Nystatin	223-226	defensin beta 103B	Homo sapiens	164-179
26763184-2	2016	Recent studies demonstrated that R. rosea had anti-inflammatory activity in animal models, for example, carrageenan- and nystatin-induced edema in rats, possibly by inhibiting phospholipase A2 and cyclooxygenases-1 and -2.	Nystatin	121-129	phospholipase A2 group IB	Rattus norvegicus	176-221
26919709-3	2016	A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits.	Nystatin	226-234	toll like receptor 2	Homo sapiens	90-94
26919709-3	2016	A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits.	Nystatin	226-234	toll like receptor 8	Homo sapiens	120-124
26318294-7	2015	The use of methyl-beta-cyclodextrin and nystatin to disrupt lipid rafts prevents the clustering of Fas and the activation of CerS6 and p38 kinase, and also inhibits STD-induced apoptosis.	Nystatin	40-48	ceramide synthase 6	Homo sapiens	125-130
26730381-4	2015	In the present results, fluoxetine, tianeptine, and milnacipran reduced glycine-induced ion current in the hippocampal CA1 neurons in nystatin-perforated patch clamp method.	Nystatin	134-142	carbonic anhydrase 1	Rattus norvegicus	119-122
26318294-7	2015	The use of methyl-beta-cyclodextrin and nystatin to disrupt lipid rafts prevents the clustering of Fas and the activation of CerS6 and p38 kinase, and also inhibits STD-induced apoptosis.	Nystatin	40-48	mitogen-activated protein kinase 14	Homo sapiens	135-138
25821818-8	2015	When stimulated by TRAIL or nystatin, CLU protein expression accompanies early phase of autophagy.	Nystatin	28-36	clusterin	Rattus norvegicus	38-41
25423047-7	2015	Expression levels of caveolin-1 in A549 and HeLa cells are different, and these differences appear to contribute to the sensitivity of TCTP-PTD uptake inhibition, against lipid-raft depleter, nystatin.	Nystatin	192-200	caveolin 1	Homo sapiens	21-31
25423047-7	2015	Expression levels of caveolin-1 in A549 and HeLa cells are different, and these differences appear to contribute to the sensitivity of TCTP-PTD uptake inhibition, against lipid-raft depleter, nystatin.	Nystatin	192-200	tumor protein, translationally-controlled 1	Homo sapiens	135-139
25640083-8	2015	Incubation of HRGECs with MBCD or nystatin, or transfection with Cav-1 siRNA, significantly reduced the intracellular amounts of albumin and Cav-1, relative to normal HRGECs, as shown by western blotting and immunofluorescence.	Nystatin	34-42	caveolin 1	Homo sapiens	141-146
24894380-6	2015	A 48-hr exposure to nystatin (15 mug/ml) was followed by a significant increase of [Ca(2+) ]i , a significant increase of annexin V binding and a significant decrease of FSC.	Nystatin	20-28	annexin A5	Homo sapiens	122-131
24894380-7	2015	The annexin V binding after nystatin treatment was significantly blunted in the nominal absence of extracellular Ca(2+) .	Nystatin	28-36	annexin A5	Homo sapiens	4-13
24798787-11	2015	In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with nystatin can potentiate the delivery and efficacy of these EGFR-targeted agents.	Nystatin	208-216	epidermal growth factor receptor	Homo sapiens	108-112
24798787-7	2015	We identified that cholesterol sequestration by nystatin enhanced cetuximab internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis.	Nystatin	48-56	epidermal growth factor receptor	Homo sapiens	95-99
24798787-7	2015	We identified that cholesterol sequestration by nystatin enhanced cetuximab internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis.	Nystatin	48-56	epidermal growth factor receptor	Homo sapiens	139-143
24798787-9	2015	Nystatin-enhanced internalization of cetuximab further improved the uptake and potency of cetuximab-doxorubicin and cetuximab-methotrexate conjugates in EGFR-positive cetuximab-resistant tumors.	Nystatin	0-8	epidermal growth factor receptor	Homo sapiens	153-157
24009857-0	2013	The cholesterol-binding antibiotic nystatin induces expression of macrophage inflammatory protein-1 in macrophages.	Nystatin	35-43	MAPK associated protein 1	Homo sapiens	66-99
23831464-0	2013	Differential regulation of CC chemokine ligand 2 and CXCL8 by antifungal agent nystatin in macrophages.	Nystatin	79-87	C-C motif chemokine ligand 2	Homo sapiens	27-48
23831464-0	2013	Differential regulation of CC chemokine ligand 2 and CXCL8 by antifungal agent nystatin in macrophages.	Nystatin	79-87	C-X-C motif chemokine ligand 8	Homo sapiens	53-58
23831464-4	2013	However, nystatin dose-dependently increased CCL2 and CXCL8 expression at the mRNA and protein levels.	Nystatin	9-17	C-C motif chemokine ligand 2	Homo sapiens	45-49
23831464-4	2013	However, nystatin dose-dependently increased CCL2 and CXCL8 expression at the mRNA and protein levels.	Nystatin	9-17	C-X-C motif chemokine ligand 8	Homo sapiens	54-59
23831464-5	2013	To understand the molecular mechanisms of the antifungal agent, we identified cellular factors activated by nystatin and those involved in nystatin-induced upregulation of CCL2 and CXCL8.	Nystatin	139-147	C-C motif chemokine ligand 2	Homo sapiens	172-176
23831464-5	2013	To understand the molecular mechanisms of the antifungal agent, we identified cellular factors activated by nystatin and those involved in nystatin-induced upregulation of CCL2 and CXCL8.	Nystatin	139-147	C-X-C motif chemokine ligand 8	Homo sapiens	181-186
23831464-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK.	Nystatin	15-23	AKT serine/threonine kinase 1	Homo sapiens	64-67
23831464-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 3	Homo sapiens	69-75
23831464-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 1	Homo sapiens	77-80
23831464-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 3	Homo sapiens	81-85
23831464-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 8	Homo sapiens	91-94
23831464-7	2013	Treatment with cholesterol, LY294002, Akt inhibitor IV, U0126, and SP6001250 resulted in abrogation or significant attenuation of nystatin-induced CCL2 expression.	Nystatin	130-138	AKT serine/threonine kinase 1	Homo sapiens	38-41
23831464-7	2013	Treatment with cholesterol, LY294002, Akt inhibitor IV, U0126, and SP6001250 resulted in abrogation or significant attenuation of nystatin-induced CCL2 expression.	Nystatin	130-138	C-C motif chemokine ligand 2	Homo sapiens	147-151
23831464-8	2013	Nystatin-mediated CXCL8 expression was attenuated in the presence of Akt inhibitor IV and SP6001250.	Nystatin	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	18-23
23831464-8	2013	Nystatin-mediated CXCL8 expression was attenuated in the presence of Akt inhibitor IV and SP6001250.	Nystatin	0-8	AKT serine/threonine kinase 1	Homo sapiens	69-72
23831464-9	2013	These results indicate that exposure of human macrophages to nystatin can lead to differential regulation of CCL2 and CXCL8 via the activation of multiple cellular kinases.	Nystatin	61-69	C-C motif chemokine ligand 2	Homo sapiens	109-113
23831464-9	2013	These results indicate that exposure of human macrophages to nystatin can lead to differential regulation of CCL2 and CXCL8 via the activation of multiple cellular kinases.	Nystatin	61-69	C-X-C motif chemokine ligand 8	Homo sapiens	118-123
23831464-10	2013	We propose that upregulation of CCL2 and CXCL8 contributes to pharmacological effects of nystatin.	Nystatin	89-97	C-C motif chemokine ligand 2	Homo sapiens	32-36
23831464-10	2013	We propose that upregulation of CCL2 and CXCL8 contributes to pharmacological effects of nystatin.	Nystatin	89-97	C-X-C motif chemokine ligand 8	Homo sapiens	41-46
23088298-9	2013	Furthermore, the high NYT concentration interfered in the internalization process of human transferrin receptor (hTfnR) while NYT-IL did not.	Nystatin	22-25	transferrin receptor	Homo sapiens	91-111
23258590-9	2013	Further studies showed that nystatin partially prevented lipid raft aggregation and DR4 and DR5 clustering and reduced apoptosis in H460 cells again.	Nystatin	28-36	TNF receptor superfamily member 10a	Homo sapiens	84-87
23258590-9	2013	Further studies showed that nystatin partially prevented lipid raft aggregation and DR4 and DR5 clustering and reduced apoptosis in H460 cells again.	Nystatin	28-36	TNF receptor superfamily member 10b	Homo sapiens	92-95
25038452-7	2014	In contrast, constitutive GPR40 internalization was not affected by hypertonic sucrose or by knock-down of clathrin expression, but it was affected by treatment with methyl-beta-cyclodextrin (MbetaCD) and nystatin.	Nystatin	205-213	free fatty acid receptor 1	Homo sapiens	26-31
24697697-8	2014	Immunofluorescence microscopy revealed that treatment with two cholesterol-chelating drugs, nystatin and filipin, significantly affected RAGE localization in MelJuSo cells.	Nystatin	92-100	advanced glycosylation end-product specific receptor	Homo sapiens	137-141
24009857-3	2013	In the current study, we investigated the question of whether nystatin was able to induce expression of macrophage inflammatory protein-1 (MIP-1).	Nystatin	62-70	MAPK associated protein 1	Homo sapiens	104-137
24009857-3	2013	In the current study, we investigated the question of whether nystatin was able to induce expression of macrophage inflammatory protein-1 (MIP-1).	Nystatin	62-70	MAPK associated protein 1	Homo sapiens	139-144
24009857-4	2013	THP-1 cells rarely express MIP-1alpha and MIP-1beta, however, upon exposure to nystatin, significantly elevated expression of MIP-1alpha and MIP-1beta was observed in a dose-dependent fashion at the messenger and protein levels.	Nystatin	79-87	C-C motif chemokine ligand 3	Homo sapiens	27-37
24009857-4	2013	THP-1 cells rarely express MIP-1alpha and MIP-1beta, however, upon exposure to nystatin, significantly elevated expression of MIP-1alpha and MIP-1beta was observed in a dose-dependent fashion at the messenger and protein levels.	Nystatin	79-87	C-C motif chemokine ligand 4	Homo sapiens	42-51
24009857-4	2013	THP-1 cells rarely express MIP-1alpha and MIP-1beta, however, upon exposure to nystatin, significantly elevated expression of MIP-1alpha and MIP-1beta was observed in a dose-dependent fashion at the messenger and protein levels.	Nystatin	79-87	C-C motif chemokine ligand 3	Homo sapiens	126-136
24009857-4	2013	THP-1 cells rarely express MIP-1alpha and MIP-1beta, however, upon exposure to nystatin, significantly elevated expression of MIP-1alpha and MIP-1beta was observed in a dose-dependent fashion at the messenger and protein levels.	Nystatin	79-87	C-C motif chemokine ligand 4	Homo sapiens	141-150
24009857-5	2013	Cellular factors activated by nystatin as well as involved in nystatin-induced expression of MIP-1 proteins were identified in order to understand the molecular mechanisms of action of the anti-fungal agent.	Nystatin	62-70	MAPK associated protein 1	Homo sapiens	93-98
24009857-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK, p38 MAPK, and JNK.	Nystatin	15-23	AKT serine/threonine kinase 1	Homo sapiens	64-67
24009857-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 14	Homo sapiens	74-77
24009857-6	2013	Treatment with nystatin resulted in enhanced phosphorylation of Akt, ERK, p38 MAPK, and JNK.	Nystatin	15-23	mitogen-activated protein kinase 8	Homo sapiens	88-91
24009857-7	2013	Abrogation or significant attenuation of nystatin-induced expression of MIP-1alpha and MIP-1beta was observed by treatment with Akt inhibitor IV, LY294002, and SP6001250.	Nystatin	41-49	C-C motif chemokine ligand 3	Homo sapiens	72-82
24009857-7	2013	Abrogation or significant attenuation of nystatin-induced expression of MIP-1alpha and MIP-1beta was observed by treatment with Akt inhibitor IV, LY294002, and SP6001250.	Nystatin	41-49	C-C motif chemokine ligand 4	Homo sapiens	87-96
24009857-7	2013	Abrogation or significant attenuation of nystatin-induced expression of MIP-1alpha and MIP-1beta was observed by treatment with Akt inhibitor IV, LY294002, and SP6001250.	Nystatin	41-49	AKT serine/threonine kinase 1	Homo sapiens	128-131
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	28-36	AKT serine/threonine kinase 1	Homo sapiens	100-103
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	28-36	mitogen-activated protein kinase 8	Homo sapiens	108-111
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	28-36	MAPK associated protein 1	Homo sapiens	165-170
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	134-142	AKT serine/threonine kinase 1	Homo sapiens	100-103
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	134-142	mitogen-activated protein kinase 8	Homo sapiens	108-111
24009857-10	2013	These results indicate that nystatin is able to activate multiple cellular kinases and, among them, Akt and JNK play primary roles in nystatin-induced expression of MIP-1 proteins.	Nystatin	134-142	MAPK associated protein 1	Homo sapiens	165-170
22798431-5	2012	Further, FP augmented apical membrane Cl(-) current (I(Cl)), reflecting cystic fibrosis transmembrane conductance regulator (CFTR)-mediated conductance, in the nystatin-permeabilized monolayer.	Nystatin	160-168	CF transmembrane conductance regulator	Homo sapiens	125-129
22863853-5	2012	Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95.	Nystatin	176-184	tissue inhibitor of metalloproteinase 1	Mus musculus	68-107
22230296-9	2012	An ERalpha/beta antagonist (ICI182780) and a selective disruptor of caveolar structures (nystatin) blocked estrogen-induced ERK activation.	Nystatin	89-97	Eph receptor B1	Rattus norvegicus	124-127
22178865-2	2012	Three characteristic effects were detected in three different nystatin concentration ranges: vesicle shape changes (between 150 and 250muM); transient, nonspecific, tension pores (between 250 and 400muM); and vesicle ruptures (above 400muM).	Nystatin	62-70	latexin	Homo sapiens	135-138
22499997-4	2012	The levels of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) and the anti-inflammatory cytokine interleukin 10 (IL-10) produced by splenocytes from mice injected with NYT-IL or nystatin were evaluated by an ELISA assay.	Nystatin	235-243	interleukin 10	Mus musculus	170-175
22863853-5	2012	Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95.	Nystatin	176-184	hepatitis A virus cellular receptor 1	Mus musculus	29-53
22863853-5	2012	Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95.	Nystatin	176-184	lipocalin 2	Mus musculus	55-66
22863853-5	2012	Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95.	Nystatin	176-184	secreted phosphoprotein 1	Mus musculus	113-138
22093622-7	2011	MGC803 cells were pretreated with 50 mg/L nystatin for 1 h, and followed by the treatment of cisplatin and TRAIL.	Nystatin	42-50	TNF superfamily member 10	Homo sapiens	107-112
21916894-10	2012	In yeast cells, AtLrgB could augment nystatin-induced membrane permeability.	Nystatin	37-45	membrane protein	Arabidopsis thaliana	16-22
21251218-10	2011	Response to CT was retained after permeabilization of the basolateral or the apical membranes of T84 cells with nystatin.	Nystatin	112-120	calcitonin related polypeptide alpha	Homo sapiens	12-14
22093622-13	2011	While, pretreatment with nystatin before the addition of cisplatin and TRAIL, the proportion of apoptotic cells decreased from (43.16 +- 4.26)% to (31.52 +- 3.99)% (P < 0.05).	Nystatin	25-33	TNF superfamily member 10	Homo sapiens	71-76
21769428-7	2011	It suggested that the TRAIL-induced redistribution of DR4 and DR5 in lipid rafts contributed to the sensitivity to TRAIL in TRAIL-sensitive NSCLC H460 cell line, which was also confirmed by intervention tests of the cholesterol-sequestering agent nystatin.	Nystatin	247-255	TNF superfamily member 10	Homo sapiens	22-27
21769428-7	2011	It suggested that the TRAIL-induced redistribution of DR4 and DR5 in lipid rafts contributed to the sensitivity to TRAIL in TRAIL-sensitive NSCLC H460 cell line, which was also confirmed by intervention tests of the cholesterol-sequestering agent nystatin.	Nystatin	247-255	TNF receptor superfamily member 10a	Homo sapiens	54-57
21769428-7	2011	It suggested that the TRAIL-induced redistribution of DR4 and DR5 in lipid rafts contributed to the sensitivity to TRAIL in TRAIL-sensitive NSCLC H460 cell line, which was also confirmed by intervention tests of the cholesterol-sequestering agent nystatin.	Nystatin	247-255	TNF receptor superfamily member 10b	Homo sapiens	62-65
21769428-7	2011	It suggested that the TRAIL-induced redistribution of DR4 and DR5 in lipid rafts contributed to the sensitivity to TRAIL in TRAIL-sensitive NSCLC H460 cell line, which was also confirmed by intervention tests of the cholesterol-sequestering agent nystatin.	Nystatin	247-255	TNF superfamily member 10	Homo sapiens	115-120
21769428-7	2011	It suggested that the TRAIL-induced redistribution of DR4 and DR5 in lipid rafts contributed to the sensitivity to TRAIL in TRAIL-sensitive NSCLC H460 cell line, which was also confirmed by intervention tests of the cholesterol-sequestering agent nystatin.	Nystatin	247-255	TNF superfamily member 10	Homo sapiens	115-120
21821762-5	2011	Nevertheless, many NysA mutants and hybrids were functional, providing for different levels of nystatin biosynthesis.	Nystatin	95-103	NYS2	Homo sapiens	19-23
21821762-6	2011	An interplay between certain residues in AT(0) and an active site residue in the ketosynthase (KS)-like domain of NysA in initiation of nystatin biosynthesis was revealed.	Nystatin	136-144	NYS2	Homo sapiens	114-118
21482707-5	2011	Intriguingly, cholesterol sequestration by nystatin, a polyene antifungal drug, significantly enhances endostatin uptake by endothelial cells through switching endostatin internalization predominantly to the clathrin-mediated pathway.	Nystatin	43-51	collagen, type XVIII, alpha 1	Mus musculus	103-113
21482707-5	2011	Intriguingly, cholesterol sequestration by nystatin, a polyene antifungal drug, significantly enhances endostatin uptake by endothelial cells through switching endostatin internalization predominantly to the clathrin-mediated pathway.	Nystatin	43-51	collagen, type XVIII, alpha 1	Mus musculus	160-170
21482707-0	2011	Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways.	Nystatin	29-37	collagen, type XVIII, alpha 1	Mus musculus	74-84
21482707-6	2011	Nystatin-enhanced internalization of endostatin also increases its inhibitory effects on endothelial cell tube formation and migration.	Nystatin	0-8	collagen, type XVIII, alpha 1	Mus musculus	37-47
21482707-7	2011	More importantly, combined treatment with nystatin and endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues but not in normal tissues of tumor-bearing mice, ultimately resulting in elevated antiangiogenic and antitumor efficacies of endostatin in vivo.	Nystatin	42-50	collagen, type XVIII, alpha 1	Mus musculus	87-97
21482707-7	2011	More importantly, combined treatment with nystatin and endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues but not in normal tissues of tumor-bearing mice, ultimately resulting in elevated antiangiogenic and antitumor efficacies of endostatin in vivo.	Nystatin	42-50	collagen, type XVIII, alpha 1	Mus musculus	87-97
21209384-6	2011	Accordingly, FLT-1 localization and its phosphorylation are abrogated by methyl-beta-cyclodextrin (MbetaCD), which removes cellular cholesterol, and by nystatin, an inhibitor of lipid-raft endocytosis.	Nystatin	152-160	fms related receptor tyrosine kinase 1	Homo sapiens	13-18
21195154-6	2011	Permeabilizing apical membrane with nystatin revealed that LGP-stimulated basolateral K(+) current was significantly inhibited by KCNQ1 K(+) channel inhibitor chromanol 293B.	Nystatin	36-44	potassium voltage-gated channel subfamily Q member 1	Rattus norvegicus	130-135
21468584-8	2011	Pretreatment with 50 microg/ml nystatin, a cholesterol-sequestering agent, partially prevented epirubicin-induced lipid raft aggregation and DR4 and DR5 clustering.	Nystatin	31-39	TNF receptor superfamily member 10a	Homo sapiens	141-144
21468584-8	2011	Pretreatment with 50 microg/ml nystatin, a cholesterol-sequestering agent, partially prevented epirubicin-induced lipid raft aggregation and DR4 and DR5 clustering.	Nystatin	31-39	TNF receptor superfamily member 10b	Homo sapiens	149-152
21468584-9	2011	Pretreatment with nystatin did not markedly inhibit epirubicin-induced apoptosis, while nystatin partially suppressed epirubicin and TRAIL-induced apoptosis (P<0.05).	Nystatin	88-96	TNF superfamily member 10	Homo sapiens	133-138
20832779-3	2010	Disruption of lipid rafts with methyl-beta-cyclodextrin, fumonisin B1 or nystatin prevented LPC-stimulated caspase-1 activation and reactive oxygen species (ROS) production, whereas LPC-induced Na(+) influx remained unaffected.	Nystatin	73-81	caspase 1	Homo sapiens	107-116
21625424-2	2011	However, amphotericin and nystatin have been reported to also trigger interleukin-1beta (IL-1beta) secretion in monocytes but the molecular mechanism is unknown.	Nystatin	26-34	interleukin 1 beta	Mus musculus	70-87
21625424-2	2011	However, amphotericin and nystatin have been reported to also trigger interleukin-1beta (IL-1beta) secretion in monocytes but the molecular mechanism is unknown.	Nystatin	26-34	interleukin 1 beta	Mus musculus	89-97
21625424-3	2011	Here we report that only the polyene macrolides amphotericin B, nystatin, and natamycin but none of the tested azole antimycotic drugs induce significant IL-1beta secretion in-vitro in dendritic cells isolated from C57BL/6 mouse bone marrow.	Nystatin	64-72	interleukin 1 beta	Mus musculus	154-162
21625424-7	2011	Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1.	Nystatin	49-57	interleukin 1 beta	Mus musculus	81-89
21625424-7	2011	Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1.	Nystatin	49-57	NLR family, pyrin domain containing 3	Mus musculus	153-158
21625424-7	2011	Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1.	Nystatin	49-57	steroid sulfatase	Mus musculus	159-162
21625424-7	2011	Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1.	Nystatin	49-57	caspase 1	Mus musculus	163-172
20561599-4	2010	SERPINA1 association with monocytes is inhibited by cholesterol depleting/efflux-stimulating agents (nystatin, filipin, MbetaCD (methyl-beta-cyclodextrin) and oxidized low-density lipoprotein (oxLDL) and conversely, enhanced by free cholesterol.	Nystatin	101-109	serpin family A member 1	Homo sapiens	0-8
20039299-4	2010	Disruption of lipid rafts integrity with nystatin or methyl beta-cyclodextrin abrogated PKCalpha PKCdelta and p38 phosphorylation, but had no effect on ERK1/2 phosphorylation.	Nystatin	41-49	protein kinase C delta	Homo sapiens	97-105
20039299-4	2010	Disruption of lipid rafts integrity with nystatin or methyl beta-cyclodextrin abrogated PKCalpha PKCdelta and p38 phosphorylation, but had no effect on ERK1/2 phosphorylation.	Nystatin	41-49	mitogen-activated protein kinase 1	Homo sapiens	110-113
19786303-3	2009	IL-8 expression was inhibited by nystatin (a lipid rafts inhibitor) but not by chlorpromazine (a clathrin-coated pits inhibitor).	Nystatin	33-41	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
19136614-7	2009	Furthermore, ex vivo treatment of rabbit thoracic aorta and carotid artery segments with nystatin prevented mCRP-induced IL-8 release.	Nystatin	89-97	interleukin-8	Oryctolagus cuniculus	121-125
19457171-4	2009	Surprisingly, treatment with nystatin induced only NO production and iNOS expression in RAW264.7 cells.	Nystatin	29-37	nitric oxide synthase 2, inducible	Mus musculus	69-73
19457171-6	2009	From studies using several kinds of inhibitors for signaling molecules, nystatin-induced NO production seems to occur via the ikappaB/NF-kappaB and the PI3 K/Akt pathway.	Nystatin	72-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	134-143
19457171-6	2009	From studies using several kinds of inhibitors for signaling molecules, nystatin-induced NO production seems to occur via the ikappaB/NF-kappaB and the PI3 K/Akt pathway.	Nystatin	72-80	thymoma viral proto-oncogene 1	Mus musculus	158-161
19457171-9	2009	The results suggest that a moderate concentration of nystatin induces NO production by Na-pump activation through the PI3 kinase/Akt/NF-kappaB pathway without affecting the condition of lipid rafts.	Nystatin	53-61	thymoma viral proto-oncogene 1	Mus musculus	129-132
19457171-9	2009	The results suggest that a moderate concentration of nystatin induces NO production by Na-pump activation through the PI3 kinase/Akt/NF-kappaB pathway without affecting the condition of lipid rafts.	Nystatin	53-61	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-142
18778304-4	2008	Treatment of RBL-2H3 cells with nystatin and progesterone, agents that disrupt organization of lipid raft/caveolae, resulted in the attenuation of anandamide and 2-arachidonyl glycerol synthesis and/or release in response to stimulation with ionomycin suggesting a role for these membrane microdomains in endocannabinoid biosynthesis.	Nystatin	32-40	RB transcriptional corepressor like 2	Rattus norvegicus	13-18
18815123-9	2009	Cholesterol extraction from the intact macrophage with methyl-beta-cyclodextrin was sufficient to activate ERK, recapitulating the LPS-IkappaB kinase-p105-MEK-ERK cascade, whereas both it and the alternate raft-disrupting agent nystatin blocked subsequent LPS activation of the ERK cascade.	Nystatin	228-236	mitogen-activated protein kinase 1	Homo sapiens	107-110
18815123-9	2009	Cholesterol extraction from the intact macrophage with methyl-beta-cyclodextrin was sufficient to activate ERK, recapitulating the LPS-IkappaB kinase-p105-MEK-ERK cascade, whereas both it and the alternate raft-disrupting agent nystatin blocked subsequent LPS activation of the ERK cascade.	Nystatin	228-236	nuclear factor kappa B subunit 1	Homo sapiens	150-154
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Nystatin	152-160	TNF receptor superfamily member 10a	Homo sapiens	205-208
19223002-4	2009	Oxaliplatin promoted death receptor 4 (DR4) and death receptor 5 (DR5) clustering into aggregated lipid rafts, while the cholesterol-sequestering agent nystatin partially prevented lipid raft aggregation, DR4 and DR5 clustering, and reduced apoptosis.	Nystatin	152-160	TNF receptor superfamily member 10b	Homo sapiens	213-216
17997161-6	2008	Interestingly, PGN-induced IL-8 expression was inhibited by nystatin, a specific inhibitor for lipid rafts, but not by chlorpromazine, a specific inhibitor for clathrin-coated pits.	Nystatin	60-68	C-X-C motif chemokine ligand 8	Homo sapiens	27-31
18629562-6	2008	In addition, nystatin can also partially inhibit the activation of NF-kappaB induced by MNNG.	Nystatin	13-21	nuclear factor kappa B subunit 1	Homo sapiens	67-76
18434319-6	2008	In contrast, cholesterol binding agents such as filipin and nystatin and the tyrosine kinase inhibitor genistein dramatically inhibited Dsg3 internalization.	Nystatin	60-68	desmoglein 3	Homo sapiens	136-140
18065769-7	2008	Confocal microscopy analyses, as well as cholesterol depletion experiments in the presence of cholesterol-depleting agents such as nystatin or methyl-beta-cyclodextrin, demonstrated that ALK1 is located in endothelial caveolae.	Nystatin	131-139	activin A receptor like type 1	Homo sapiens	187-191
19136727-3	2008	In this study, NALDI/SiNWs and ITO were tested as potentially useful DESI substrates for selected model analytes (cyclosporine, beauverolide, surfactin and nystatin).	Nystatin	156-164	desumoylating isopeptidase 2	Homo sapiens	69-73
18048366-7	2008	Also consistent with the turgor hypothesis is the observation that reduced turgor caused by treatment of cells with nystatin, a drug that increases membrane permeability and causes cell shrinkage, reduced Sln1p kinase activity (Tao, W., Deschenes, R. J., and Fassler, J. S. (1999) J. Biol.	Nystatin	116-124	histidine kinase	Saccharomyces cerevisiae S288C	205-210
18275112-4	2008	Nystatin was employed to study lipid rafts since it could disrupt lipid rafts structure.The EGF receptors, ASM and lipid rafts were labeled with polyclonal anti-EGFR antibody, anti-ASM antibody and FITC-Cholera toxin B, respectively.	Nystatin	0-8	sphingomyelin phosphodiesterase 1	Homo sapiens	107-110
18275112-4	2008	Nystatin was employed to study lipid rafts since it could disrupt lipid rafts structure.The EGF receptors, ASM and lipid rafts were labeled with polyclonal anti-EGFR antibody, anti-ASM antibody and FITC-Cholera toxin B, respectively.	Nystatin	0-8	sphingomyelin phosphodiesterase 1	Homo sapiens	181-184
17049593-8	2007	PBS was used for nystatin release with addition of surfactants and water was used for the study on drug loading and surfactant release.	Nystatin	17-25	cholinergic receptor muscarinic 3	Homo sapiens	0-3
17876056-6	2007	Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells.	Nystatin	0-8	TNF superfamily member 10	Homo sapiens	123-128
17878231-5	2007	Conversely, cholesterol-lowering agents (fluvastatin and lovastatin) and cholesterol-depleting agents (beta-cyclodextrin and nystatin) enhance TGF-beta responsiveness by increasing non-lipid raft microdomain accumulation of TGF-beta receptors and facilitating TGF-beta-induced signaling.	Nystatin	125-133	transforming growth factor, beta 1	Mus musculus	143-151
17878231-5	2007	Conversely, cholesterol-lowering agents (fluvastatin and lovastatin) and cholesterol-depleting agents (beta-cyclodextrin and nystatin) enhance TGF-beta responsiveness by increasing non-lipid raft microdomain accumulation of TGF-beta receptors and facilitating TGF-beta-induced signaling.	Nystatin	125-133	transforming growth factor, beta 1	Mus musculus	224-232
17878231-5	2007	Conversely, cholesterol-lowering agents (fluvastatin and lovastatin) and cholesterol-depleting agents (beta-cyclodextrin and nystatin) enhance TGF-beta responsiveness by increasing non-lipid raft microdomain accumulation of TGF-beta receptors and facilitating TGF-beta-induced signaling.	Nystatin	125-133	transforming growth factor, beta 1	Mus musculus	224-232
17049593-11	2007	RESULTS: The release of nystatin was low in PBS and its release rate increased with the addition of surfactants.	Nystatin	24-32	cholinergic receptor muscarinic 3	Homo sapiens	44-47
17049593-16	2007	Nystatin release in PBS is low owing to its poor solubility.	Nystatin	0-8	cholinergic receptor muscarinic 3	Homo sapiens	20-23
16267108-2	2006	In nystatin-perforated current-clamped cells, S1P hyperpolarized the membrane and simultaneously increased [Ca(2+)](i).	Nystatin	3-11	membrane bound transcription factor peptidase, site 1	Homo sapiens	46-49
17226785-5	2007	The VSMC line PAC-1 activates the MAP kinase Erk in response to the cholesterol-sequestering agents methyl-beta-cyclodextrin and nystatin.	Nystatin	129-137	ADCYAP receptor type I	Homo sapiens	14-19
17226785-5	2007	The VSMC line PAC-1 activates the MAP kinase Erk in response to the cholesterol-sequestering agents methyl-beta-cyclodextrin and nystatin.	Nystatin	129-137	mitogen-activated protein kinase 1	Homo sapiens	45-48
17170070-3	2007	In nystatin-perforated whole-cell patches from NPM cells, which leave the intracellular integrity intact, OT transiently increased BKCa-mediated outward currents (Iout).	Nystatin	3-11	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	131-135
17139247-0	2006	GLUT4 is internalized by a cholesterol-dependent nystatin-sensitive mechanism inhibited by insulin.	Nystatin	49-57	solute carrier family 2 member 4	Homo sapiens	0-5
17139247-0	2006	GLUT4 is internalized by a cholesterol-dependent nystatin-sensitive mechanism inhibited by insulin.	Nystatin	49-57	insulin	Homo sapiens	91-98
17139247-3	2006	Approximately 80% of GLUT4 is internalized by a mechanism that is sensitive to the cholesterol-aggregating drug nystatin, and is independent of AP-2 clathrin adaptor and two putative GLUT4 endocytic motifs.	Nystatin	112-120	solute carrier family 2 member 4	Homo sapiens	21-26
17139247-4	2006	The remaining GLUT4 is internalized by an AP-2-dependent, nystatin-resistant pathway that requires the FQQI GLUT4 motif.	Nystatin	58-66	solute carrier family 2 member 4	Homo sapiens	14-19
17139247-4	2006	The remaining GLUT4 is internalized by an AP-2-dependent, nystatin-resistant pathway that requires the FQQI GLUT4 motif.	Nystatin	58-66	solute carrier family 2 member 4	Homo sapiens	108-113
17139247-5	2006	Insulin inhibits GLUT4 uptake by the nystatin-sensitive pathway and, consequently, GLUT4 is internalized by the AP-2-dependent pathway in stimulated adipocytes.	Nystatin	37-45	insulin	Homo sapiens	0-7
17139247-5	2006	Insulin inhibits GLUT4 uptake by the nystatin-sensitive pathway and, consequently, GLUT4 is internalized by the AP-2-dependent pathway in stimulated adipocytes.	Nystatin	37-45	solute carrier family 2 member 4	Homo sapiens	17-22
17139247-5	2006	Insulin inhibits GLUT4 uptake by the nystatin-sensitive pathway and, consequently, GLUT4 is internalized by the AP-2-dependent pathway in stimulated adipocytes.	Nystatin	37-45	solute carrier family 2 member 4	Homo sapiens	83-88
17108132-4	2006	Treatment of 2008 cells with DDP in combination with inhibitors of various endosomal pathways (amiloride, cytochalasin D, nystatin, and methyl-beta-cyclodextrin) showed that hCTR1 degradation was blocked by amiloride and cytochalasin D, indicating that hCTR1 was internalized primarily by macropinocytosis.	Nystatin	122-130	solute carrier family 31 member 1	Homo sapiens	174-179
17346672-3	2007	However, in the cells that had been depleted of cholesterol with Nystatin or methyl-beta-cyclodextrin, the diffusion rate of TbetaRI was not changed by TGF-beta1 treatment.	Nystatin	65-73	transforming growth factor beta receptor 1	Homo sapiens	125-132
17079792-8	2007	Modification of lipid rafts by cyclodextrin and nystatin corrected the abnormal response, suggesting an association between the increased lipid rafts and abnormal TNF-alpha secretion.	Nystatin	48-56	tumor necrosis factor	Mus musculus	163-172
16945147-10	2006	By contrast, treatment of cells with nystatin to inhibit lipid raft function, prevented the uptake of apoE-VLDL by Syn-1.	Nystatin	37-45	apolipoprotein E	Homo sapiens	102-106
16945147-10	2006	By contrast, treatment of cells with nystatin to inhibit lipid raft function, prevented the uptake of apoE-VLDL by Syn-1.	Nystatin	37-45	syndecan 1	Homo sapiens	115-120
16492675-5	2006	Receptor-bound 125I-TGF-beta1 undergoes nystatin-inhibitable rapid degradation in CHO-K1 cells but not in CHO-677 cells.	Nystatin	40-48	transforming growth factor beta-1 proprotein	Cricetulus griseus	20-29
16492675-6	2006	In Mv1Lu cells (which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound 125I-TGF-beta1), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (<1) to a high (>1) ratio of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I and enhanced TGF-beta1-induced transcriptional activation of PAI-1.	Nystatin	50-58	transforming growth factor beta-1 proprotein	Cricetulus griseus	112-121
16492675-6	2006	In Mv1Lu cells (which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound 125I-TGF-beta1), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (<1) to a high (>1) ratio of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I and enhanced TGF-beta1-induced transcriptional activation of PAI-1.	Nystatin	50-58	transforming growth factor beta-1 proprotein	Cricetulus griseus	267-276
16492675-6	2006	In Mv1Lu cells (which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound 125I-TGF-beta1), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (<1) to a high (>1) ratio of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I and enhanced TGF-beta1-induced transcriptional activation of PAI-1.	Nystatin	50-58	transforming growth factor beta-1 proprotein	Cricetulus griseus	267-276
16492675-6	2006	In Mv1Lu cells (which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound 125I-TGF-beta1), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (<1) to a high (>1) ratio of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I and enhanced TGF-beta1-induced transcriptional activation of PAI-1.	Nystatin	50-58	plasminogen activator inhibitor 1	Cricetulus griseus	372-377
16162868-6	2005	Using the nystatin-perforated patch-clamp technique, we found that IRL-1620 caused an increase in Ca(2+) current that was inhibited by addition of ET-1.	Nystatin	10-18	endothelin-1	Oryctolagus cuniculus	147-151
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	histocompatibility-2, MHC	Mus musculus	116-122
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	CD40 antigen	Mus musculus	125-129
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	intercellular adhesion molecule 1	Mus musculus	131-135
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	CD80 antigen	Mus musculus	137-141
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	CD86 antigen	Mus musculus	147-151
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	interleukin 1 beta	Mus musculus	227-235
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	interleukin 6	Mus musculus	237-241
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	tumor necrosis factor	Mus musculus	250-277
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	chemokine (C-C motif) ligand 3	Mus musculus	283-321
16171455-9	2006	Additionally, DRM-disrupting agents, such as nystatin and methyl-beta-cyclodextrin, alter cellular responses to CD16b receptor ligation.	Nystatin	45-53	Fc gamma receptor IIIb	Homo sapiens	112-117
16236826-11	2006	In addition, inhibition of ERK1/2 reduces Na(+)-K(+)-ATPase activity (measured as stimulation of Qo(2) by carbachol and the cationophore nystatin).	Nystatin	137-145	mitogen activated protein kinase 3	Rattus norvegicus	27-33
16344372-6	2006	In isolated LR fractions from Fas-stimulated endothelial cells, gp91phox, p47phox (a crucial cytosolic regulatory subunit of NADPH oxidase), and Rac GTPase were markedly increased and blocked by nystatin, a compound that disrupts LRs.	Nystatin	195-203	dual oxidase 2	Homo sapiens	125-138
16477145-5	2005	In the present study, we investigated the expression of the transient receptor potential vanilloid subfamily member 1 (TRPV1) channel--which essentially contributes to the detection of pain sensation--in rat odontoblasts by immunohistochemical and nystatin perforated patch-clamp techniques.	Nystatin	248-256	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	119-124
16181427-8	2005	TAT-mediated protein delivery in neuronal cells occurs through a lipid raft-dependent endocytotic process, inhibited by the cholesterol-sequestering agent nystatin.	Nystatin	155-163	Tat	Human immunodeficiency virus 1	0-3
15879522-3	2005	Consistent with altered cell surface properties, kti6 cells resist hygromycin B, syringomycin E, and nystatin, antibiotics that require intact membrane potentials or provoke membrane disruption.	Nystatin	101-109	inositolphosphotransferase	Saccharomyces cerevisiae S288C	49-53
16156791-6	2005	Functional analysis showed that the deletion of OSH6 led to a significant increase in total cellular ergosterols, whereas OSH6 overexpression caused both a significant decrease in ergosterol levels and resistance to nystatin.	Nystatin	216-224	oxysterol-binding protein OSH6	Saccharomyces cerevisiae S288C	122-126
15896296-7	2005	EtOH or nystatin, a lipid raft-disrupting drug, suppressed LPS-induced production of TNF-alpha.	Nystatin	8-16	tumor necrosis factor	Mus musculus	85-94
16048981-0	2005	Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.	Nystatin	0-8	interleukin 1 beta	Homo sapiens	30-52
16048981-0	2005	Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.	Nystatin	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	54-58
16048981-0	2005	Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.	Nystatin	0-8	tumor necrosis factor	Homo sapiens	64-91
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	interleukin 1 beta	Homo sapiens	45-67
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	tumor necrosis factor	Homo sapiens	79-106
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	toll like receptor 1	Homo sapiens	143-163
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	toll like receptor 1	Homo sapiens	165-169
16048981-2	2005	Herein, we demonstrate that nystatin induces interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha secretion through its activation of toll-like receptor 1 (TLR1) and TLR2.	Nystatin	28-36	toll like receptor 2	Homo sapiens	175-179
15882443-7	2005	Hepatocyte growth factor receptor internalization was prevented by overexpression of dominant negative mutants of dynamin 1 and epidermal growth factor phosphorylation substrate 15, but not caveolin 1, the GTPase Arf6 or the cholesterol-chelating drug Nystatin.	Nystatin	252-260	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	0-33
15796901-3	2005	It was shown that MNNG-induced EGFR clustering occurred primarily at lipid rafts, as nystatin, which can disrupt lipid raft structure, significantly decreasing MNNG-induced EGFR clustering.	Nystatin	85-93	epidermal growth factor receptor	Homo sapiens	31-35
15796901-3	2005	It was shown that MNNG-induced EGFR clustering occurred primarily at lipid rafts, as nystatin, which can disrupt lipid raft structure, significantly decreasing MNNG-induced EGFR clustering.	Nystatin	85-93	epidermal growth factor receptor	Homo sapiens	173-177
15796901-6	2005	Nystatin treatment also abolished the redistribution of ASM.	Nystatin	0-8	sphingomyelin phosphodiesterase 1	Homo sapiens	56-59
15579537-2	2004	With nystatin-perforated recording, the magnitude and time courses of activation and inactivation of carbachol (CCh; 100 microM)-activated TRPC6 currents (I(TRPC6)) were enhanced and accelerated, respectively, by extracellular Ca2+ (Ca2+(o)) whether it was continuously present or applied after receptor stimulation.	Nystatin	5-13	transient receptor potential cation channel subfamily C member 6	Homo sapiens	139-144
15827618-8	2005	Additionally, rsp5 strains were resistant to nystatin, which binds to ergosterol present in the plasma membrane, and sensitive to calcofluor white, a drug destabilizing cell wall integrity by binding to chitin.	Nystatin	45-53	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	14-18
15802195-1	2005	In this study we use nystatin perforated-patch and conventional whole-cell recording to characterize the biophysical properties of neuronal nitric oxide synthase (nNOS)-expressing paraganglion neurons from the rat glossopharyngeal nerve (GPN), that are thought to provide NO-mediated efferent inhibition of carotid body chemoreceptors.	Nystatin	21-29	nitric oxide synthase 1	Rattus norvegicus	163-167
15579537-2	2004	With nystatin-perforated recording, the magnitude and time courses of activation and inactivation of carbachol (CCh; 100 microM)-activated TRPC6 currents (I(TRPC6)) were enhanced and accelerated, respectively, by extracellular Ca2+ (Ca2+(o)) whether it was continuously present or applied after receptor stimulation.	Nystatin	5-13	transient receptor potential cation channel subfamily C member 6	Homo sapiens	157-162
15213059-4	2004	SPI-0211 increased electrogenic Cl- transport across the apical membrane of T84 cells, with an EC50 of approximately 18 nM measured by short-circuit current (Isc) after permeabilization of the basolateral membrane with nystatin.	Nystatin	219-227	chromogranin A	Homo sapiens	0-3
15474513-5	2004	Nystatin permeabilization studies confirmed that the SMase- and C2-ceramide-induced repressions were due to hindrance of augmentation of cystic fibrosis transmembrane conductance regulator (CFTR)-mediated conductance across the apical membrane.	Nystatin	0-8	CF transmembrane conductance regulator	Homo sapiens	137-188
15474513-5	2004	Nystatin permeabilization studies confirmed that the SMase- and C2-ceramide-induced repressions were due to hindrance of augmentation of cystic fibrosis transmembrane conductance regulator (CFTR)-mediated conductance across the apical membrane.	Nystatin	0-8	CF transmembrane conductance regulator	Homo sapiens	190-194
14622130-7	2003	P-gp in isolated caveolae is able to bind its substrates, and the caveolae-disrupting agents filipin III and nystatin decrease P-gp transport activity.	Nystatin	109-117	phosphoglycolate phosphatase	Bos taurus	0-4
15290301-8	2004	Such an unusual increase of the amplitude could be prevented by adding ATP to the pipette solution or by recording with the nystatin-perforated patch-clamp technique, suggesting that the rupture of patch membrane affected the behaviour of Na(v)1.9.	Nystatin	124-132	sodium channel, voltage-gated, type XI, alpha	Mus musculus	239-247
15219865-1	2004	We have monitored the ligand binding of the bovine hippocampal 5-HT1A receptor following treatment with the sterol-binding antifungal antibiotic nystatin.	Nystatin	145-153	5-hydroxytryptamine receptor 1A	Bos taurus	63-69
15219865-2	2004	Nystatin considerably inhibits the specific binding of the antagonist to 5-HT1A receptors in a concentration-dependent manner.	Nystatin	0-8	5-hydroxytryptamine receptor 1A	Bos taurus	73-79
15084590-8	2004	Antagonism of TGF-beta1-dependent Smad signaling and the effect of HA on TGF-beta receptor associations were inhibited by depletion of membrane cholesterol using nystatin and augmented by inhibition of endocytosis.	Nystatin	162-170	transforming growth factor beta 1	Homo sapiens	14-23
15084590-8	2004	Antagonism of TGF-beta1-dependent Smad signaling and the effect of HA on TGF-beta receptor associations were inhibited by depletion of membrane cholesterol using nystatin and augmented by inhibition of endocytosis.	Nystatin	162-170	transforming growth factor beta 1	Homo sapiens	14-22
15150117-4	2004	The cholesterol sequestering agent nystatin also prevents cisplatin-induced CD95 clustering and decreases HT29 cell sensitivity to cisplatin-induced apoptosis and the synergy between cisplatin and anti-CD95 agonistic antibodies.	Nystatin	35-43	Fas cell surface death receptor	Homo sapiens	76-80
15150117-4	2004	The cholesterol sequestering agent nystatin also prevents cisplatin-induced CD95 clustering and decreases HT29 cell sensitivity to cisplatin-induced apoptosis and the synergy between cisplatin and anti-CD95 agonistic antibodies.	Nystatin	35-43	Fas cell surface death receptor	Homo sapiens	202-206
15150117-6	2004	Interestingly, nystatin prevents the translocation of the aSMase to the extracellular surface of plasma membrane and the production of ceramide, suggesting that these early events require raft integrity.	Nystatin	15-23	sphingomyelin phosphodiesterase 1	Homo sapiens	58-64
15150117-7	2004	In addition, nystatin prevents cisplatin-induced transient increase in plasma membrane fluidity that could be required for CD95 translocation.	Nystatin	13-21	Fas cell surface death receptor	Homo sapiens	123-127
14644562-2	2003	In this work, a 7-nitrobenz-2-oxa-1,3-diazole (NBD) hexanoyl amide derivative of nystatin was synthesized and its detailed photophysical characterization is presented.	Nystatin	81-89	OXA1L mitochondrial inner membrane protein	Homo sapiens	30-35
12941963-3	2003	We also demonstrated that BDNF rapidly induced a sustained potentiation of GABAA receptor-mediated currents, using nystatin-perforated patch clamp recordings, in visual cortical layer 5 pyramidal neurons freshly isolated from P14 rats.	Nystatin	115-123	brain-derived neurotrophic factor	Rattus norvegicus	26-30
14622130-7	2003	P-gp in isolated caveolae is able to bind its substrates, and the caveolae-disrupting agents filipin III and nystatin decrease P-gp transport activity.	Nystatin	109-117	phosphoglycolate phosphatase	Bos taurus	127-131
12821642-3	2003	Reductions in turgor caused by either hyperosmotic stress, nystatin, or removal of cell wall activate MAPK Hog1 specifically through the SLN1 branch, but not through the SHO1 branch of the high osmolarity glycerol pathway.	Nystatin	59-67	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	107-111
12464396-3	2003	In the present study, the modulatory effect of COX-2 on glycine- and glutamate-induced ion currents in periaqueductal gray (PAG) neurons was investigated using the nystatin-perforated patch clamp method.	Nystatin	164-172	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	47-52
12730953-4	2003	With nystatin-perforated patch clamp, thapsigargin activated a current that reversed near the Cl(-) reversal potential, which was blocked by Cl(-) channel blockers, 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) and Zn(2+), by I(-) (10 mM), and by chlorotoxin (EC(50) = 47 nM).	Nystatin	5-13	natriuretic peptide B	Rattus norvegicus	207-211
12519745-6	2003	Activation of endogenous AMPK with the cell-permeant adenosine analog 5-amino-4-imidazolecarboxamide-1-beta-d-ribofuranoside (AICAR) inhibited forskolin-stimulated CFTR-dependent I(sc) in nonpermeabilized monolayers and monolayers with nystatin permeabilization of the basolateral membrane.	Nystatin	236-244	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	25-29
12640007-2	2003	We demonstrate that BDNF (20 ng ml-1) rapidly and reversibly potentiates postsynaptic GABAA receptor-mediated currents (by 80.5 +/- 14.3 %, n = 10) in hippocampal CA1 pyramidal neurons isolated from postnatal day (P)6 rats, using nystatin-perforated patch-clamp recordings.	Nystatin	230-238	brain-derived neurotrophic factor	Rattus norvegicus	20-24
12529272-6	2003	PAF at 1 nM maximally inhibited Qo(2) in both untreated and nystatin-stimulated (sodium entry into renal cell is not rate limiting) proximal tubules by approximately 20%.	Nystatin	60-68	PCNA clamp associated factor	Rattus norvegicus	0-3
12529272-7	2003	Blockade of PAF receptors or Na(+)-K(+)-ATPase pump activity with BN-52021 or ouabain, respectively, abolished the effect of PAF on nystatin-stimulated proximal tubule Qo(2).	Nystatin	132-140	PCNA clamp associated factor	Rattus norvegicus	12-15
12529272-7	2003	Blockade of PAF receptors or Na(+)-K(+)-ATPase pump activity with BN-52021 or ouabain, respectively, abolished the effect of PAF on nystatin-stimulated proximal tubule Qo(2).	Nystatin	132-140	PCNA clamp associated factor	Rattus norvegicus	125-128
12014897-16	2002	There are several specific risk factors for particular NAC species: C. parapsilosis is related to foreign body insertion, neonates and hyperalimentation; C. krusei to azole prophylaxis and along with C. tropicalis to neutropenia and BMT; C. glabrata to azole prophylaxis, surgery and urinary or vascular catheters; C. lusitaniae and C. guilliermondii to previous polyene (amphotericin B or nystatin) use; and C. rugosa to burns.	Nystatin	390-398	synuclein alpha	Homo sapiens	55-58
12045230-5	2002	Lipid raft integrity is essential for LPS-cellular activation, since raft-disrupting drugs, such as nystatin or MCD, inhibit LPS-induced TNF-alpha secretion.	Nystatin	100-108	tumor necrosis factor	Homo sapiens	137-146
11691871-7	2001	Slow whole-cell recordings, using nystatin-perforated patches from transfected CHO-K1 cells, also produced voltage-dependent Cl(-) currents consistent with ClC-5 expression.	Nystatin	34-42	chloride channel, voltage-sensitive 5	Mus musculus	156-161
11350754-4	2001	TGF-alpha (0.17 nM) irreversibly inhibited ClC-2 current in nystatin-perforated whole cell patch-clamp experiments, whereas a superimposed reversible activation of the current was observed at 8.3 nM TGF-alpha.	Nystatin	60-68	transforming growth factor alpha	Homo sapiens	0-9
11598382-3	2001	Nystatin perforated patch recording of Ca(2+)-dependent potassium currents was used to monitor GnRH-induced [Ca(2+)](i) changes.	Nystatin	0-8	gonadotropin releasing hormone 1	Rattus norvegicus	95-99
11350754-4	2001	TGF-alpha (0.17 nM) irreversibly inhibited ClC-2 current in nystatin-perforated whole cell patch-clamp experiments, whereas a superimposed reversible activation of the current was observed at 8.3 nM TGF-alpha.	Nystatin	60-68	chloride voltage-gated channel 2	Homo sapiens	43-48
10692447-2	2000	In both assays, agonist-dependent internalization of myc-ETA was inhibited by nystatin and filipin, both of which disrupt internalization via caveolae, whereas it was barely affected by chlorpromazine and hypertonic sucrose, both of which disrupt internalization via clathrin-coated pits.	Nystatin	78-86	endothelin-1 receptor	Cricetulus griseus	57-60
11101647-1	2000	Nystatin-perforated patch recordings were made from mechanically dissociated basolateral amygdala neurons with preserved intact native presynaptic nerve terminals to study the mechanism of 5-HT3 receptor-mediated serotonergic modulation of GABAergic inhibition.	Nystatin	0-8	5-hydroxytryptamine receptor 3A	Rattus norvegicus	189-203
10862715-8	2000	An alternative route for PKC(alpha) is evidenced by the finding that the cholesterol binding drugs nystatin and filipin, known to inhibit caveolae mediated trafficking, are able to block PKC(alpha) traffic and down regulation.	Nystatin	99-107	protein kinase C alpha	Homo sapiens	25-34
10862715-8	2000	An alternative route for PKC(alpha) is evidenced by the finding that the cholesterol binding drugs nystatin and filipin, known to inhibit caveolae mediated trafficking, are able to block PKC(alpha) traffic and down regulation.	Nystatin	99-107	protein kinase C alpha	Homo sapiens	187-196
11265777-3	2001	The authors performed a prospective, randomized, double-blind, placebo-controlled trial involving 64 patients to evaluate the effect of prophylactic administration of nystatin or placebo on the development of oral irritation in patients receiving high-dose intravenous IL-2.	Nystatin	167-175	interleukin 2	Homo sapiens	269-273
11114899-6	2001	Reduced SEC20 expression in the PCK1p-SEC20 strain did not affect morphogenesis but led to a series of hypersensitivity phenotypes including supersensitivity to aminoglycoside antibiotics, to nystatin, to sodium dodecyl sulfate, and to cell wall inhibitors.	Nystatin	192-200	Sec20p	Saccharomyces cerevisiae S288C	8-13
11114899-6	2001	Reduced SEC20 expression in the PCK1p-SEC20 strain did not affect morphogenesis but led to a series of hypersensitivity phenotypes including supersensitivity to aminoglycoside antibiotics, to nystatin, to sodium dodecyl sulfate, and to cell wall inhibitors.	Nystatin	192-200	phosphoenolpyruvate carboxykinase PCK1	Saccharomyces cerevisiae S288C	32-37
11063737-3	2000	Mutations in the novel gene, ARV1, render cells dependent on sterol esterification for growth, nystatin-sensitive, temperature-sensitive, and anaerobically inviable.	Nystatin	95-103	sterol homeostasis protein ARV1	Saccharomyces cerevisiae S288C	29-33
10692447-3	2000	In addition to myc-ETA, ET-1 caused intracellular translocation of caveolin-1 and this translocation was also blocked by nystatin but not by chlorpromazine.	Nystatin	121-129	caveolin-1	Cricetulus griseus	67-77
10427694-7	1999	All of the vacuolar deficient mutants (vps11, vps16, vps18, and vps33) were sensitive to nystatin.	Nystatin	89-97	tethering complex subunit PEP5	Saccharomyces cerevisiae S288C	39-44
10640318-4	2000	In nystatin-permeabilized monolayers, chlorzoxazone stimulated a basolateral membrane I(K), which was inhibited by CTX and also stimulated an apical I(Cl) that was inhibited by glibenclamide, indicating that the G(Cl) responsible for this I(Cl) may be cystic fibrosis transmembrane conductance regulator (CFTR).	Nystatin	3-11	CF transmembrane conductance regulator	Homo sapiens	252-303
10640318-4	2000	In nystatin-permeabilized monolayers, chlorzoxazone stimulated a basolateral membrane I(K), which was inhibited by CTX and also stimulated an apical I(Cl) that was inhibited by glibenclamide, indicating that the G(Cl) responsible for this I(Cl) may be cystic fibrosis transmembrane conductance regulator (CFTR).	Nystatin	3-11	CF transmembrane conductance regulator	Homo sapiens	305-309
10464063-5	1999	The ATPase-dependent Na(+) pump and Na(+)-K(+)-2Cl(-) co-transport activities were assessed from Na(+)-loaded red blood cells by using nystatine, in the presence of furosemide and ouabain, as appropriate.	Nystatin	135-144	dynein axonemal heavy chain 8	Homo sapiens	4-10
10409300-2	1999	ANG-(1-7) inhibited nystatin-stimulated, ouabain-suppressible O(2) consumption (QO(2)) rates in freshly isolated rat proximal tubules (reflecting reduced basolateral Na(+)-K(+)-ATPase activity).	Nystatin	20-28	angiogenin	Rattus norvegicus	0-8
10409300-6	1999	Metabolism of (125)I-ANG-(1-7) in rat proximal tubules generated peptide fragments that included ANG-(3-7), with the pentapeptide producing a concentration-dependent inhibition of nystatin-stimulated proximal tubule QO(2) that was abolished by AT(4)-receptor blockade.	Nystatin	180-188	angiogenin	Rattus norvegicus	21-29
10427694-7	1999	All of the vacuolar deficient mutants (vps11, vps16, vps18, and vps33) were sensitive to nystatin.	Nystatin	89-97	tethering complex subunit VPS16	Saccharomyces cerevisiae S288C	46-51
10427694-7	1999	All of the vacuolar deficient mutants (vps11, vps16, vps18, and vps33) were sensitive to nystatin.	Nystatin	89-97	tethering complex subunit PEP3	Saccharomyces cerevisiae S288C	53-58
10427694-7	1999	All of the vacuolar deficient mutants (vps11, vps16, vps18, and vps33) were sensitive to nystatin.	Nystatin	89-97	tethering complex ATP-binding subunit VPS33	Saccharomyces cerevisiae S288C	64-69
9242182-5	1997	ET-1 suppressed the basal IK by 20.9 +/- 2.3% in a concentration-dependent manner, with an IC50 of 1.1 +/- 0.3 nmol/L (n = 19), although it did not suppress the basal IK using the nystatin method.	Nystatin	180-188	endothelin-1	Cavia porcellus	0-4
10375648-1	1999	To understand the mechanism(s) underlying the Cd2+- and Co2+-induced increases in the cytosolic free Ca2+ concentration ([Ca]i) in cat adrenal chromaffin cells, we used nystatin-perforated patch recording method and fura-2 microfluorometry.	Nystatin	169-177	CD2 molecule	Canis lupus familiaris	46-49
10075710-5	1999	Fyn activation was also observed in nystatin-permeabilized cells, where shrinkage cannot induce intracellular alkalinization.	Nystatin	36-44	tyrosine-protein kinase Fyn	Cricetulus griseus	0-3
9521846-5	1998	Treating non-transfected cells or cells overexpressing mutant dynamin with nystatin caused a redistribution of the caveolae membrane marker protein VIP21-caveolin from the cell surface to intracellular locations, but did not affect their sensitivity to ricin.	Nystatin	75-83	caveolin 3	Homo sapiens	148-153
9556221-1	1998	The alteration in the fluorescence spectra observed for the polyene antibiotics: nystatin and amphotericin B in the presence of human serum albumin is due to a decrease in the polar character of the antibiotic environment when these are bound to the protein.	Nystatin	81-89	albumin	Homo sapiens	140-147
9556221-7	1998	Conformational change induced by the temperature in the albumin molecule was detected by nystatin binding.	Nystatin	89-97	albumin	Homo sapiens	56-63
8666664-4	1996	Here, we show that the GPI-anchored CD59 molecule on Jurkat T cells is internalized after cross-linking, a process inhibited by nystatin, a sterol chelating agent.	Nystatin	128-136	CD59 molecule (CD59 blood group)	Homo sapiens	36-40
9271207-5	1997	While sensitivity to several drugs is not altered, the mic2 mutant strain becomes resistant to the polyene antibiotic nystatin.	Nystatin	118-126	inositolphosphotransferase	Saccharomyces cerevisiae S288C	55-59
9096065-10	1997	AII-induced ISC was also observed in monolayers whose basolateral membranes had been permeabilized by nystatin, suggesting that the ISC was mediated by apical Cl- channels.	Nystatin	102-110	angiotensinogen	Homo sapiens	0-3
8944655-11	1996	With the use of nystatin perforated-patch current clamp to measure membrane potential, ANG II was observed to induce large transient membrane depolarizations, consistent with activation of an inward current.	Nystatin	16-24	angiotensinogen	Rattus norvegicus	87-93
8635732-1	1996	The ERG5 gene from Saccharomyces cerevisiae was cloned by complementation of an erg5-1 mutation using a negative selection protocol involving screening for nystatin-sensitive transformants.	Nystatin	156-164	C-22 sterol desaturase	Saccharomyces cerevisiae S288C	4-8
8919915-5	1996	Transformation of an erg 3 strain with this plasmid led to CH resistance, nystatin sensitivity and an ergosterol profile.	Nystatin	74-82	C-5 sterol desaturase	Saccharomyces cerevisiae S288C	21-26
7707223-11	1994	Insulin administered to nystatin-treated epithelia increased the values for both capacitances.	Nystatin	24-32	insulin	Homo sapiens	0-7
7721938-8	1995	Further, functional studies indicated that the localization of uPAR and its ligand in caveolae enhances pericellular plasminogen activation, since treatment of the cells with drugs that interfere with the structural integrity of caveolae, such as nystatin, markedly reduced cell surface plasmin generation.	Nystatin	247-255	plasminogen activator, urokinase receptor	Homo sapiens	63-67
7614555-2	1995	Transformation by CDR1 of a PDR5-disrupted host hypersensitive to cycloheximide and chloramphenicol resulted in resistance to cycloheximide, chloramphenicol and other drugs, such as the antifungal miconazole, with collateral hypersensitivity to oligomycin, nystatin and 2,4 dinitrophenol.	Nystatin	257-265	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	28-32
8769832-6	1996	Stimulating Na-K-adenosinetriphosphatase (Na-K-ATPase) activity with nystatin caused a leftward shift of the inhibitory concentration-response curve to ANG-(1-7).	Nystatin	69-77	angiopoietin 1	Rattus norvegicus	152-160
8751279-6	1995	Conventional whole-cell patch-clamp recording was used to measure inward membrane current in the absence of GnRH treatment, with and without 10 nM estradiol-17beta (E2) treatment for 0 to 36 h. Nystatin-perforated whole-cell patch-clamp recording was used to record membrane voltage responses to GnRH.	Nystatin	194-202	Progonadoliberin-1	Ovis aries	296-300
1311522-4	1992	PTH inhibited the percent nystatin-stimulated QO2 in a concentration-dependent manner, with maximal effect at 10(-10) M. PTH-increased cAMP formation was seen at doses higher than 10(-9) M and was maximal at 10(-7) M. Dibutyryl cAMP (10(-4) M) only partially reproduced the PTH action on QO2.	Nystatin	26-34	parathyroid hormone	Rattus norvegicus	0-3
7892112-1	1994	The presence of functional alpha 2-adrenoceptors was investigated in isolated smooth muscle cells from rat portal vein using the nystatin-perforated patch-clamp technique.	Nystatin	129-137	adrenoceptor alpha 2A	Rattus norvegicus	27-48
7531199-8	1994	When the basolateral cellular membrane of cells grown in vitrogen-coated filters was permeabilized with nystatin, a forskolin-stimulated Cl- permeability was observed in the apical membrane, similar to that present in other CFTR-expressing epithelial cells.	Nystatin	104-112	CF transmembrane conductance regulator	Rattus norvegicus	224-228
7515578-8	1994	Experiments in which the basolateral membrane was permeabilized with nystatin indicated that CFTR was substantially activated under baseline conditions and that Ca-activated Cl- channels were absent from the apical membrane.	Nystatin	69-77	CF transmembrane conductance regulator	Homo sapiens	93-97
8145166-2	1993	Membrane currents activated by thyrotrophin-releasing hormone (TRH) were investigated in the dissociated rat hippocampal CA1 pyramidal neurone using the nystatin perforated patch recording configuration.	Nystatin	153-161	thyrotropin releasing hormone	Rattus norvegicus	31-61
8145166-2	1993	Membrane currents activated by thyrotrophin-releasing hormone (TRH) were investigated in the dissociated rat hippocampal CA1 pyramidal neurone using the nystatin perforated patch recording configuration.	Nystatin	153-161	thyrotropin releasing hormone	Rattus norvegicus	63-66
1418625-1	1992	A sterol C-14 reductase (erg24-1) mutant of Saccharomyces cerevisiae was selected in a fen1, fen2, suppressor background on the basis of nystatin resistance and ignosterol (ergosta-8,14-dienol) production.	Nystatin	137-145	delta(14)-sterol reductase	Saccharomyces cerevisiae S288C	25-30
1311522-4	1992	PTH inhibited the percent nystatin-stimulated QO2 in a concentration-dependent manner, with maximal effect at 10(-10) M. PTH-increased cAMP formation was seen at doses higher than 10(-9) M and was maximal at 10(-7) M. Dibutyryl cAMP (10(-4) M) only partially reproduced the PTH action on QO2.	Nystatin	26-34	parathyroid hormone	Rattus norvegicus	121-124
1311522-4	1992	PTH inhibited the percent nystatin-stimulated QO2 in a concentration-dependent manner, with maximal effect at 10(-10) M. PTH-increased cAMP formation was seen at doses higher than 10(-9) M and was maximal at 10(-7) M. Dibutyryl cAMP (10(-4) M) only partially reproduced the PTH action on QO2.	Nystatin	26-34	parathyroid hormone	Rattus norvegicus	121-124
34342264-5	2021	Raft perturbation via nystatin and resveratrol significantly altered DR4/raft colocalization and TRAIL sensitivity.	Nystatin	22-30	TNF receptor superfamily member 10a	Homo sapiens	69-72
2198267-3	1990	The ura3 host was isolated by mutagenesis and a double-selection procedure that combined nystatin enrichment selection and 5-fluoro-orotic acid resistance selection.	Nystatin	89-97	orotidine-5'-phosphate decarboxylase	Saccharomyces cerevisiae S288C	4-8
2283670-6	1990	TFEC (1 mM) increased cytosolic free calcium levels 36%, had no effect on basal oxygen consumption, and decreased nystatin-stimulated oxygen consumption 30% after 5 minutes.	Nystatin	114-122	transcription factor EC	Rattus norvegicus	0-4
2154126-8	1990	Carbidopa, an inhibitor of L-AADC, abolished the L-dopa-induced inhibition of nystatin-stimulated QO2 in cells from HS rats and was without significant effect in cells from LS rats.	Nystatin	78-86	dopa decarboxylase	Rattus norvegicus	29-33
12149231-7	2002	T5A7-induced Lyn phosphorylation in neutrophil DIM fraction was significantly enhanced by cholesterol depletion or sequestration with methyl-beta-cyclodextrin or nystatin.	Nystatin	162-170	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	13-16
34992350-8	2021	Upon overexpression of caveolin-1 (CAV-1) and utilization of caveolae/lipid-raft disruptors, we found that temporal CAV-1 upregulation significantly facilitated T-DM1 endocytosis and degradation, whereas nystatin and lovastatin disrupted caveolae/lipid-raft structure and inhibited T-DM1 degradation.	Nystatin	204-212	DM1 protein kinase	Homo sapiens	284-287
34438042-4	2021	The cholesterol-interacting agent, nystatin, which binds cholesterol without removing it from the membrane, synergized with DCA to induce IL-6 and IL-8.	Nystatin	35-43	interleukin 6	Homo sapiens	138-142
34438042-4	2021	The cholesterol-interacting agent, nystatin, which binds cholesterol without removing it from the membrane, synergized with DCA to induce IL-6 and IL-8.	Nystatin	35-43	C-X-C motif chemokine ligand 8	Homo sapiens	147-151
34342264-5	2021	Raft perturbation via nystatin and resveratrol significantly altered DR4/raft colocalization and TRAIL sensitivity.	Nystatin	22-30	TNF superfamily member 10	Homo sapiens	97-102
34067824-3	2021	In this study, we uncovered the role of TRPM4 in regulating the intrinsic excitability plasticity of pyramidal neurons in the mouse mPFC layer of 2/3 using a combination of conventional and nystatin perforated whole-cell recordings.	Nystatin	190-198	transient receptor potential cation channel, subfamily M, member 4	Mus musculus	40-45
34381770-7	2021	The internalization of S100B-Alexa488 was inhibited by pitstop-2 or dyngo-4a treatment or RNA-mediated silencing of clathrin or dynamin, and the lipid raft-mediated endocytosis inhibitors nystatin and MbetaCD.	Nystatin	188-196	S100 calcium binding protein B	Homo sapiens	23-28
6363386-1	1984	Various nystatin-resistant mutants defective in S-adenosylmethionine: delta 24-sterol-C-methyltransferase (EC 2.1.1.41) were shown to possess alleles of the same gene, erg6.	Nystatin	8-16	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	168-172
34738720-3	2022	The fluoresence intensity was linearly dependant on the nystatin concentration within the specified range 50-500 ng ml-1 .	Nystatin	56-64	interleukin 17F	Homo sapiens	116-120
2694950-1	1989	Polyclonal antibodies elicited by injection into rabbits of a nystatin-bovine serum albumin conjugate were reactive with both nystatin and amphotericin B.	Nystatin	62-70	albumin	Oryctolagus cuniculus	78-91
2694950-1	1989	Polyclonal antibodies elicited by injection into rabbits of a nystatin-bovine serum albumin conjugate were reactive with both nystatin and amphotericin B.	Nystatin	126-134	albumin	Oryctolagus cuniculus	78-91
2541250-3	1989	Red blood cells with different cell Na+ (Nai) and pH (pHi) were prepared by nystatin and DIDS treatment of acid-loaded cells.	Nystatin	76-84	glucose-6-phosphate isomerase	Homo sapiens	54-57
2558958-3	1989	A ras1 strain transformed with this plasmid was subjected to ethyl methanesulfonate mutagenesis and nystatin enrichment.	Nystatin	100-108	Ras family GTPase RAS1	Saccharomyces cerevisiae S288C	2-6
2677674-12	1989	However, erg6 delta cells exhibit pleiotropic phenotypes that include defective conjugation, hypersensitivity to cycloheximide, resistance to nystatin, a severely diminished capacity for genetic transformation, and defective tryptophan uptake.	Nystatin	142-150	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	9-13
6422986-8	1984	Exposure of the mucosal surface to the ionophore nystatin abolished the Ca2+ sensitivity of the transcellular conductance, showing that the Ca2+-sensitive conductance resides in the apical membrane.	Nystatin	49-57	carbonic anhydrase 2	Homo sapiens	72-75
6422986-8	1984	Exposure of the mucosal surface to the ionophore nystatin abolished the Ca2+ sensitivity of the transcellular conductance, showing that the Ca2+-sensitive conductance resides in the apical membrane.	Nystatin	49-57	carbonic anhydrase 2	Homo sapiens	140-143
13465596-0	1957	[Nystatin prevention & therapy in patients subject to the effects of ACTH, corticoids & antibiotics].	Nystatin	1-9	proopiomelanocortin	Homo sapiens	73-77
1180530-0	1975	[Study of the fructosediphosphate aldolase and transketolase activity in the nystatin producer, Actinomyces noursei].	Nystatin	77-85	transketolase	Homo sapiens	47-60
1180530-1	1975	Activity of transketolase, an enzyme of the pentose cycle and fructosodiphosphataldolase, an enzyme of glycolisis was studied in the dynamics of development of the nystatin-producing organism and its inactive mutant under various conditions of their cultivation with a purpose of finding relation between the antibiotic production and general metabolism of Act.	Nystatin	164-172	transketolase	Homo sapiens	12-25
6626612-4	1983	The PCB- uptake was inhibited by nystatin added to the incubation mixture containing proteoliposomes when the latter were reconstituted in the presence of nystatin.	Nystatin	33-41	pyruvate carboxylase	Homo sapiens	4-7
6626612-4	1983	The PCB- uptake was inhibited by nystatin added to the incubation mixture containing proteoliposomes when the latter were reconstituted in the presence of nystatin.	Nystatin	155-163	pyruvate carboxylase	Homo sapiens	4-7
327215-3	1977	Like the other B-cell mitogens such as bacterial lipopolysaccharide (LPS), nystatin elicited nonspecifically polyclonal antibody synthesis in mouse spleen cell cultures, and also restored antibody response of T cell-deficient spleen cells of congenitally athymic nude mice to heterologous erythrocytes (RBC; thymus-dependent antigen).	Nystatin	75-83	toll-like receptor 4	Mus musculus	69-72
62740-5	1976	When a fixative mixture of methanol:acetic acid:formalin (85:5:10 by volume; MAF) is used, the concentration of nuclear solids during NYS staining remain at a physiological level of 19 per cent.	Nystatin	134-137	MAF bZIP transcription factor	Homo sapiens	77-80
33637695-6	2021	Nystatin-mediated cholesterol sequestration significantly inhibited YAP expression under SOAT1 inhibition.	Nystatin	0-8	Yes1 associated transcriptional regulator	Homo sapiens	68-71
33637695-6	2021	Nystatin-mediated cholesterol sequestration significantly inhibited YAP expression under SOAT1 inhibition.	Nystatin	0-8	sterol O-acyltransferase 1	Homo sapiens	89-94
33637695-7	2021	Moreover, nystatin synergized with the SOAT1 inhibitor avasimibe in suppressing the viability of colon cancer cells in vitro and in vivo.	Nystatin	10-18	sterol O-acyltransferase 1	Homo sapiens	39-44
32005701-7	2020	Drugs that disrupt cholesterol-enriched domains - such as nystatin and methyl-beta-cyclodextrin - decreased CD39 enzymatic activity in all circumstances.	Nystatin	58-66	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	108-112
33082354-10	2020	Lipid raft/caveolae disruptors (methyl-beta-cyclodextrin (MCD) and Nystatin) and Ang II stimulation variably increased O2- generation and phosphorylation of MLC20, Ezrin-Radixin-Moesin (ERM) and p53 but not ERK1/2, effects recapitulated in Cav-1 silenced (siRNA) VSMCs.	Nystatin	67-75	myosin light chain 12B	Homo sapiens	157-162
32290618-4	2020	Here, we aimed to compare the effect of cyclodextrin (MbetaCD)- and nystatin-induced cholesterol modulations on stress-activated expression of the representative HSPs, HSP70, and HSP25 in mouse B16-F10 melanoma cells.	Nystatin	68-76	heat shock protein 1	Mus musculus	179-184
32290618-6	2020	Sequestration of cholesterol with nystatin impaired the heat-inducibility of HSP25 but not of HSP70.	Nystatin	34-42	heat shock protein 1	Mus musculus	77-82
32317932-7	2020	At elevated concentrations, Nystatin promotes growth cone expansion through phosphorylation of Akt; whereas, at low concentrations, Nystatin enhances axon length and regrowth by increasing nitric oxide levels.	Nystatin	28-36	AKT serine/threonine kinase 1	Homo sapiens	95-98
31990231-4	2020	Candida isolates were tested for their ability to produce proteinase and phospholipase as well as for their susceptibility to fluconazole and nystatin.Results: Proteinase production was higher in non-albicans Candida (NAC) isolates of IUD users compared with non-users (p = 0.017).	Nystatin	142-150	endogenous retrovirus group K member 25	Homo sapiens	160-170